Showing results (181-190 of 1,988) with videos related to
Sort By:
Pageof 199
Breast Cancer Research and Treatment|March 17, 2022
Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancerYun Wu, Yiqun Han, Qing Li, et al.Plos One|May 29, 2015
Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer RegistriesWenjie Zhu, Edith A Perez, Ruoxi Hong, et al.Cancer Chemotherapy and Pharmacology|February 10, 2011
Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumorsPin Zhang, Mingyuan Sun, Rongguo Qiu, et al.Cancer Medicine|May 22, 2022
Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysisHangcheng Xu, Yiqun Han, Yun Wu, et al.Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|June 25, 2026
Prognostic significance of ctDNA mutations in advanced HER2-positive breast cancer treated with targeted therapy: A meta-analysisJialin Lin, Hangcheng Xu, Yiran Zhou, et al.International Journal of Cancer|June 27, 2020
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in ChinaYimeng Chen, Yin Guan, Jiayu Wang, et al.Breast (Edinburgh, Scotland)|April 9, 2025
The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world studyXuenan Peng, Bo Lan, Jiayu Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2017
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast CancerFei Ma, Qiao Li, Shanshan Chen, et al.Cancer Communications (London, England)|January 5, 2019
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancerXiuwen Guan, Fei Ma, Chunxiao Li, et al.Cancer Treatment Reviews|May 19, 2015
The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumorsJiuda Zhao, Feng Du, Yang Luo, et al.Pageof 199